APA citáció

Heier Jeffrey S., Khanani Arshad M., Ruiz Carlos Quezada, Basu Karen, Ferrone Philip J., Brittain Christopher, . . . Kollaborációs szervezet: TENAYA and LUCERNE Investigators. (2022). Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials.

Chicago Style (17th ed.) Citation

Heier Jeffrey S., et al. Efficacy, Durability, and Safety of Intravitreal Faricimab Up to Every 16 Weeks for Neovascular Age-related Macular Degeneration (TENAYA and LUCERNE): Two Randomised, Double-masked, Phase 3, Non-inferiority Trials. The Lancet Publishing Group, 2022.

MLA idézés

Heier Jeffrey S., et al. Efficacy, Durability, and Safety of Intravitreal Faricimab Up to Every 16 Weeks for Neovascular Age-related Macular Degeneration (TENAYA and LUCERNE): Two Randomised, Double-masked, Phase 3, Non-inferiority Trials. 2022.